

In Press: November 2nd, 2009, *Pediatric Pulmonology*

An elevated bronchodilator response predicts large airway inflammation in mild asthma

James L. Puckett, PhD¹, Richard W.E. Taylor, BS¹, Szu-Yun, Leu, PhD⁴, Olga L. Guijon, MD⁵, Anna S. Aledia, BS^{1,3}, Stanley P. Galant, MD^{5,#}, and Steven C. George, MD, PhD^{1,2,*,#}

Department of Biomedical Engineering¹, Chemical Engineering and Materials Science², and Medicine³, Institute for Clinical Translational Science⁴, University of California, Irvine, Irvine, CA 92697, Children's Hospital of Orange County⁵, Orange, CA 92697, USA.

Authors contributed equally to this manuscript

Abbreviated title: BDR and large airway nitric oxide

*Corresponding Author:

Steven C. George, M.D., Ph.D.
Department of Biomedical Engineering
2420 Engineering Hall
University of California, Irvine
Irvine, California 92697-2730
Telephone: (949) 824-3941
Fax: (949) 824-9968
email: scgeorge@uci.edu.

ABSTRACT

Exhaled nitric oxide (eNO) is elevated in asthmatics and is a purported marker of airway inflammation. The bronchodilator response (BDR) has also been shown to correlate with markers of airway inflammation, including eNO at 50 ml/s ($FE_{NO,50}$) which is comprised of NO from both the proximal and distal airways. Using eNO at multiple flows and a two-compartment model of NO exchange, the eNO signal can be partitioned into its proximal [J'_{awNO} (nl/s)] and distal contributions [CA_{NO} (ppb)]. We hypothesized that the BDR reflects the inflammatory status of the larger airways with smooth muscle, and thus would correlate with J'_{awNO} . In 179 predominantly (95%) Hispanic children with mild asthma (69 steroid naïve), and 21 non-asthmatic non-atopic controls, spirometry and eNO at multiple flows were measured prior and ten minutes following inhalation of albuterol. A trumpet-shaped axial diffusion model of NO exchange was used to characterize J'_{awNO} and CA_{NO} . The BDR correlated moderately ($r=0.44$) with proximal airway NO (J'_{awNO}), but weakly ($r=0.26$) with distal airway/alveolar NO (CA_{NO}), and only in inhaled corticosteroid naïve asthmatics. A BDR cut point as low as $\geq 8\%$ had a positive predictive value of 83% for predicting an elevated J'_{awNO} or $FE_{NO,50}$. We conclude that the BDR reflects inflammation in the large airways, and may be an effective clinical tool to predict elevated large airway inflammation.

Key words: nitric oxide, inflammation, NO, pulmonary function

INTRODUCTION

Asthma is a chronic inflammatory disease which can involve all parts of the respiratory tract¹⁻³ and airway inflammation may still be present in even seemingly well controlled asthmatics⁴. Research in adults with asthma has demonstrated that improved control can be achieved through the use of surrogate markers of airway inflammation to modulate asthma treatment rather than waiting for symptoms to recrudescence or lung function to decline^{5,6}. Thus, there is a need for a simple, non-invasive index of airway inflammation in children, ideally customized to manage the inflammation and prevent disease sequelae.

Exhaled nitric oxide (eNO) at a flow of 50 ml/s ($FE_{NO,50}$) is significantly elevated in the majority of steroid naïve asthmatics⁷, reduced upon administration of oral and inhaled corticosteroids (ICS)^{8,9} and is thus generally accepted to be a non-invasive biological marker of airway inflammation¹⁰. Longitudinal studies have investigated the use of $FE_{NO,50}$ as an index of asthma control^{4,11-13}. The results of these studies have been mixed, as two studies demonstrated that $FE_{NO,50}$ was not predictive in reducing the dose of corticosteroid or predicting exacerbation^{11,13}. Furthermore, $FE_{NO,50}$ is inherently non-specific regarding the origin of NO in the lungs¹⁴ and the recommended exhalation flow of 50 ml/s¹⁵ is low enough to cause the concentration to be predominately of proximal airway origin¹⁶; hence, the distal contributions are effectively ignored. However, by applying simple mathematical models of pulmonary NO dynamics, the eNO signal can be partitioned into proximal airway [J'_{awNO} , (nl/s), maximum airway flux, generations 1-16] and distal airway/alveolar contributions [CA_{NO} , (ppb), alveolar NO concentration, generations 17-23]. Increased J'_{awNO} with normal CA_{NO} has been

reported in adults ¹⁷ and children ¹⁸ with mild asthma, whereas CA_{NO} is increased in asthmatics with enhanced symptoms and more severe disease ^{16,18,19}. Furthermore, J'_{awNO} and CA_{NO} have been shown to correlate with markers of airway inflammation and airway dysfunction ²⁰. These findings indicate distinct patterns of airway inflammation in asthma, and suggest that the region-specific eNO parameters (i.e., J'_{awNO} and CA_{NO}) provide information of possible clinical utility.

The bronchodilator response (BDR), currently recommended for the diagnosis of asthma ¹, is an easily administered test that is widely available to clinicians. It has more recently been thought to reflect bronchial lability ²¹ and could represent a surrogate marker of airway inflammation ²²⁻²⁴, airway remodeling ²⁵, and responsiveness to ICS ^{26,27}. A key finding relating BDR to airway inflammation in children has been its relationship to $FE_{NO,50}$ ^{22,24,28}. However, the relationship between BDR and both J'_{awNO} and CA_{NO} in asthma has not been reported, but could potentially enhance the clinical interpretation of the BDR.

The purpose of this study was to evaluate the relationship of the BDR to $FE_{NO,50}$, J'_{awNO} and CA_{NO} in children with mild asthma. We hypothesized that the BDR, as a marker of bronchial lability, reflects the inflammatory status of the larger smooth muscle containing airways. Thus, the BDR would correlate with J'_{awNO} and may be a simple yet useful test to assess large airway inflammation in children with mild asthma.

METHODS

Study Subjects

Two hundred consecutive patients with asthma who presented to the Children's Hospital of Orange County (CHOC) Breathmobile® for an asthma evaluation participated in the study. Criteria for the diagnosis of asthma included a previous history of recurrent coughing, wheezing, shortness of breath (at rest or following exercise), and symptomatic improvement following short acting bronchodilator ¹. Patients were excluded from the study if they had any other heart or lung disease, any smoking within the past five years, or they were treated with inhaled corticosteroids for less than 8 weeks. Short and long acting β_2 agonists were withheld for 12 hours prior to the study. Additionally, twenty-one children without asthma were enrolled in the study to serve as non-asthmatic controls. The inclusion criteria for the non-asthmatics included no history or clinical evidence of acute or chronic respiratory disease, non-atopic, and normal spirometry. Each subject and their guardian began their visit by reading and completing the requirements stated in the informed consent documents; the consent form had been approved by the University of California, Irvine and CHOC Institutional Review Boards.

Study Design and Methods

Skin prick tests were performed by the nurse and assessed by the physician. The skin prick test revealed atopy to common aeroallergens (cat, dog, feathers, cockroach, dust mites, mold, weeds, trees and grasses), and the patient was considered atopic if positive to at least one antigen. Asthma symptoms were quantified

using the validated Asthma Control Test (ACT) for children (age 6 – 11 years) ²⁹ and adults (age 12 – 17 years) ³⁰.

The eNO measurements at multiple flows (50 ml/s, 100 ml/s and 200 ml/s; NIOX Flex, Aerocrine Ltd, Stockholm, Sweden) were performed prior to the pre-bronchodilator spirometric maneuver. The order of the exhalation flows were randomized and eNO measurements were performed in triplicate at each flow, in accordance with ATS/ERS guidelines ¹⁵.

Standard spirometry was performed (WinDx Spirometer, Creative Biomedics International, CA) in accordance with ATS criteria ³¹. To determine the bronchodilator response (BDR), albuterol (180 mcg; 2 puff with spacer) was appropriately administered. The subjects were asked to wait 10 minutes for the medication to take effect, before repeating the eNO measurements and spirometry. The BDR was calculated as the percent change in FEV₁ following administration of albuterol.

Analysis

The average eNO concentration at each flow was calculated following current ATS/ERS guidelines ¹⁵. During an eNO maneuver, a steady state mean alveolar or distal airway/alveolar concentration (CA_{NO} , ppb) enters the conducting airway compartment (net transfer is convection minus diffusion) where upon additional NO is transferred from the airway walls ($J'aw_{NO}$, nl/s). Based on the structure of the validated trumpet-shaped two-compartment model with axial diffusion ³², the proximal airway NO flux or $J'aw_{NO}$ represents the signal from the conducting region of the lungs (Weibel generations 1-16), and the distal airway/alveolar concentration or CA_{NO} represents the

signal from the respiratory region of the lungs (Weibel generations 17-23). We then applied a linear least squares analysis to a plot of the average NO elimination rate (product of average eNO and average flow) versus the average exhalation flow to estimate J'_{awNO} (nl/s, maximum airway flux) and CA_{NO} (ppb, alveolar NO concentration)

33

Data are reported using median and range (minimum-maximum), or number of subjects and proportion. Clinical characteristics were compared among the asthmatics and non-asthmatic controls using the Kruskal-Wallis and the chi-square test. For variables with significant differences among the groups, paired comparisons were applied with Bonferroni's multiple comparison adjustment. Spearman rank-order correlation and Spearman partial rank-order correlation were calculated to examine the strength of associations amongst age, the BDR, other spirometric measurements, and eNO measurements within ICS naïve and ICS treated groups. Thus, the correlation was considered, regardless of p-value, strong if the absolute value was >0.7 , moderate if it ranged between 0.3 and 0.7, weak if it ranged between 0.1 and 0.3, and no correlation if <0.1 . We further applied different cut points of BDR to calculate sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV). Significance level was set at 0.05 and analysis was performed using SAS 9 (Cary, NC).

RESULTS

Baseline patient characteristics

Two hundred children with asthma, and twenty-one non-asthmatic non-atopic children between the ages of 6-17 years were enrolled into the study. In both study populations 95% of the participants reported an ethnicity of Hispanic. All of the enrolled subjects were able to perform the eNO, and baseline spirometric maneuvers. However, among the asthmatic subjects, one subject was excluded due to missing spirometric data, and twenty were excluded from the analysis since their eNO did not fit the linear model of NO exchange; this was due to a negative estimated CA_{NO} (i.e., non-physiologic interpretation). Data on the BDR was collected in 167 of the remaining 179 children with asthma and in 13 of the non-asthmatic non-atopic children.

The non-asthmatic control and asthmatic pre-bronchodilator characteristics are shown in Table 1. In this table the asthmatics were stratified on the basis of ICS use. ICS naïve was defined as no oral or ICS within the last 8 weeks and ICS treated was defined as prescribed ICS treatment for at least 8 weeks. The study groups were similar in age, gender and ethnicity. With regards to atopic status, approximately 80% of the asthmatics tested positive to one or more of the common aeroallergens. A significant group difference was found in FEV1/FVC ($p=0.03$), where the ICS treated group was significantly lower than non-asthmatic non-atopic group, as well as the ACT score ($p=0.007$) in which the ICS treated group had a higher score than ICS naïve. No other significant differences in pre-bronchodilator spirometry were observed between the non-asthmatic controls and asthmatics, independent of ICS use.

The BDR and pre-bronchodilator exhaled nitric oxide parameters are presented in Table 2. No difference was found in BDR, but a significant group difference was found in all three nitric oxide measurements, where $FE_{NO,50}$, $J'aw_{NO}$ and CA_{NO} were

significantly higher in the ICS naïve group compared to ICS treated group, and $FE_{NO,50}$ and $J'aw_{NO}$ were also significantly higher in both the ICS naïve group and ICS treated group compared to non-asthmatic controls.

Non-asthmatic values for $J'aw_{NO}$ and CA_{NO}

By measuring eNO at multiple flows in 21 non-asthmatic non-atopic children we were able to estimate the upper limits of normal for $FE_{NO,50}$, $J'aw_{NO}$ and CA_{NO} . In the non-asthmatic children, the median and range of $FE_{NO,50}$, $J'aw_{NO}$ and CA_{NO} were found to be 8.5 (2.2-15.3) ppb, 0.7 (0.1 – 1.4) nl/s and 1.5 (0.1 – 2.2) ppb, respectively. Analysis of this distribution and rounding up the maximum value to two significant digits provides a conservative estimate of a threshold for elevated exhaled NO, proximal airway NO and distal airway/alveolar NO in our subject populations: $FE_{NO,50} \geq 16$ ppb , $J'aw_{NO} \geq 1.5$ nl/s and $CA_{NO} \geq 2.3$ ppb. These results are similar to the findings of other reports using the two compartment model¹⁴ to partition eNO in non-asthmatic children^{16,34} when adjusting for the effect of axial diffusion of NO.

Correlations with pulmonary function tests and eNO

In our data, age was either only weakly correlated or not correlated with pulmonary function or eNO (ranged between -0.28 and 0.30). In the ICS naïve group, the BDR had a moderately positive correlation with $FE_{NO,50}$ ($r = 0.46$) and $J'aw_{NO}$ ($r = 0.44$), a weak correlation with CA_{NO} ($r = 0.26$) (Fig.1), and a moderately negative correlation with FEV_1/FVC ($r = -0.51$) and percent predicted FEF_{25-75} ($r = -0.48$). Also, FEV_1/FVC was found to have a moderately negative correlation with $FE_{NO,50}$ ($r = -0.39$) and $J'aw_{NO}$ ($r = -0.38$), and a weak correlation with CA_{NO} ($r = -0.21$). The partial

correlation between BDR and $FE_{NO,50}$ (or $J'aw_{NO}$) was further calculated to remove possible influence of FEV_1/FVC , and the correlation reduced to 0.31 for $FE_{NO,50}$ and 0.29 for $J'aw_{NO}$. In the ICS treated group, the BDR only weakly correlated with $FE_{NO,50}$ ($r = 0.18$) and $J'aw_{NO}$ ($r = 0.19$), and did not correlate with CA_{NO} ($r = 0.005$) (Fig.1). Gender did not impact the pattern of correlations. Furthermore, only 37 children (10 ICS naïve and 27 ICS treated) non-atopic asthmatic children completed the BDR measurement, and thus atopic and non-atopic were not evaluated separately.

Sensitivity and Specificity of eNO with various BDR threshold

Since BDR had the highest correlations with $FE_{NO,50}$ and $J'aw_{NO}$ in the ICS naïve subjects, we evaluated various cut points of BDR to find a potential optimal threshold to predict an elevated $FE_{NO,50}$ (≥ 16 ppb) and elevated $J'aw_{NO}$ (≥ 1.5 nl/s). At a BDR of 12%, the sensitivity, specificity, PPV, and NPV for $J'aw_{NO}$ was 0.31, 1.00, 1.00, and 0.34, respectively. The corresponding values for $FE_{NO,50}$ were nearly identical; the only difference being a NPV of 0.32. Lowering the BDR cutoff step wise in 1% intervals to 8% resulted in increased sensitivity, decreased specificity, decreased PPV, and decreased NPV (Table 3). Of interest was a PPV of 0.83 for a BDR cut point of 8% for both elevated $FE_{NO,50}$ and elevated $J'aw_{NO}$.

DISCUSSION

Our study has investigated the relationship between the BDR, proximal airway ($FE_{NO,50}$ and $J'aw_{NO}$) and distal airway/alveolar (CA_{NO}) NO in both ICS naïve and ICS treated mild pediatric asthma populations. Our main finding is the positive correlation

between the BDR and non-invasive markers of inflammation in the proximal airways in ICS naïve asthmatic children only (Fig. 1), and a positive predictive value of 83% for a BDR as low as 8% for predicting (or ruling in) elevated large airway nitric oxide. This result improves our understanding of the BDR and suggests that bronchodilator-induced changes in FEV₁ reflect, in part, large airway inflammation.

Most physicians have access only to spirometry as an objective measure to assess asthma disease activity. However, several studies have found inconsistent or poor relationships between lung function and asthma symptoms or severity in children, because many asthmatic children have near normal spirometric values even when they demonstrate symptoms of persistent asthma³⁵. In our study, we found no difference in baseline spirometry between ICS naïve and ICS treated asthmatics, and only a small difference between FEV₁/FVC in our control group and the ICS treated group (Table 1). These results suggest that in children with mild asthma, ICS use may not be related to baseline spirometry.

In contrast to baseline spirometry, the BDR is a dynamic measure of bronchodilation from baseline. Previous research has demonstrated a weak yet significantly relevant, positive relationship between the BDR and FE_{NO,50}, in either mixed (ICS treated and ICS naïve)^{22,28}, or ICS naïve²⁴ pediatric asthma populations, which is consistent with our results (Fig. 1). However, we have shed insight into the relationship between the BDR and region specific eNO, i.e., J_{awNO} and CA_{NO}, in separate ICS treated and ICS naïve populations. Our observation that ICS treatment, which primarily targets the proximal airways, is associated with a lower FE_{NO,50}, and J_{awNO} (Table 2), and abolishes the positive relationship (Fig. 1) strongly suggests that the BDR is closely

linked to proximal airway inflammation. These results are consistent with the findings that ICS induced reduction of peripheral airway eosinophils (assessed using bronchial biopsy) is associated with an attenuation of bronchodilator responsiveness²³. Furthermore, inflammation in the distal airways/alveoli is only weakly associated with the BDR (Fig. 1). This finding is consistent with the scant smooth muscle from the terminal bronchioles (~ generation > 14) and beyond and the two-compartment model partitioning of the airways in the proximal airway compartment (generations 0-16) and the distal airways/alveoli (generations 17-23).

The current definition of a positive BDR, $\geq 12\%$ reversibility and ≥ 200 ml increase in initial FEV₁, has been established primarily in adults¹. However, there is no clear consensus about what constitutes a positive BDR in children with asthma. Studies have suggested that BDR $\geq 9\%$ distinguishes children with asthma from children without asthma^{36,37}. It has also been reported that patients with at least a 12% BDR had significantly higher FE_{NO,50}²². A recent study by Sharma et al.³⁸ suggested that consistent BDR $\geq 12\%$ was associated with poor long term control and increased morbidity. However, subjects who had a BDR of $\geq 10\%$ had clinical outcomes similar to those with a BDR of $\geq 12\%$, suggesting that a lower BDR threshold may be appropriate in children with asthma³⁸. Our results indicate that if the BDR is $\geq 8\%$, there is a very high probability (> 83%, PPV) that FE_{NO,50} and J'aw_{NO} will also be elevated. In other words, the BDR may be a good tool to predict (or rule in), but a poor tool to rule out, elevated proximal airway NO. In concurrence with previous reports³⁸, our findings suggest that the guideline criteria defining a "positive" BDR as $\geq 12\%$ may be too high in children with asthma.

The clinical usefulness of ruling-in large airway nitric oxide using the BDR is not known. The evidence of using $FE_{NO,50}$, which is closely correlated with J'_{awNO} , to predict steroid-responsiveness³⁹, diagnose asthma⁴⁰, or checking compliance with ICS⁴¹ suggest a clinical utility. Unfortunately, several recent longitudinal studies have examined the potential of using $FE_{NO,50}$ to monitor and treat asthma^{12,13,42-44}, and have not been able to determine a specific clinical benefit, such as reducing exacerbations, when compared to traditional guidelines (e.g., symptoms, spirometry). However, asthma randomized treatment algorithm (ASTRAL) studies require very specific design criteria, and these early studies examining $FE_{NO,50}$ as a basis for managing asthma have serious design issues as recently reviewed⁴⁵. Hence, the potential role of $FE_{NO,50}$ (or large airway NO and potentially BDR) on asthma management has not been firmly established.

Our pediatric population was predominately Hispanic. Ethnicity may impact response to inhaled bronchodilators due to genetic differences in β_2 receptors⁴⁶. However, our results are consistent with previous studies with respect to the significant positive relationship (albeit weak) between $FE_{NO,50}$ and the BDR. The upper limit for $FE_{NO,50}$ (≥ 16 ppb) is lower than that reported in a recent multicenter trial in which the upper limit of normal in children 4-17 years was 25 ppb⁴⁷. This may be due to the relatively small number of control subjects in our study, the predominantly Hispanic population, or, more likely, the absence of atopic children. Only 0.8% of the children in the multicenter trial reported an ethnicity of Hispanic, while 14% were atopic. The presence of atopy increases $FE_{NO,50}$ ^{48,49}. The results for the range and upper limit of J'_{awNO} and CA_{NO} are similar to the findings of other reports using the two compartment

model¹⁴ to partition eNO in non-asthmatic children^{16,34} when adjusting for the effect of axial diffusion of NO. However, a large database of proximal and distal NO values has yet to be reported, and values in our patient population may be lower than other ethnic groups based on FE_{NO,50}.

An additional feature of the study is that 10% of the patients did not fit the two compartment model of NO exchange in the lungs. However, the model was successfully applied in all of the non-asthmatic non-atopic children. These results are similar to the findings of Paraskakis et al.¹⁶, and may be related to heterogeneous ventilation and inflammation patterns in some asthmatic subjects⁵⁰ which is not captured by the single path two-compartment model. It may be appropriate to apply a multi-compartment model of NO exchange dynamics to these children to characterize proximal and distal nitric oxide⁵¹. Finally, our population can be characterized clinically and by spirometry as mild asthmatics; hence, one might predict a small response to a bronchodilator (e.g., baseline FEV₁ near the “ceiling”). However, BDR peaks in children 8-9 years of age⁵² which may contribute to our observation of a significant BDR and a moderate relationship between large airway NO and BDR. In addition, a stronger correlation may be present in a more severe population of children that has a lower baseline FEV₁ and more inflammation.

In summary, the BDR shows moderate correlation with proximal or large airway (FE_{NO,50}, J'aw_{NO}) nitric oxide only in ICS naïve children with mild asthma, and thus suggests that the BDR reflects, in part, inflammation in the large airways. Although the traditional positive BDR cut point has been $\geq 12\%$, a value as low as $\geq 8\%$ may have

utility in the context of pediatric asthma as a simple technique to predict large airway inflammation and thus potential responsiveness to ICS.

ACKNOWLEDGEMENTS

This work was supported by a grant from the National Institutes of Health (R01 HL070645) and the Children's Hospital of Orange County.

FIGURE LEGENDS

Figure 1. Relationship between bronchodilator response and exhaled nitric oxide parameters. The exhaled nitric oxide at 50 ml/s ($FE_{NO,50}$) and proximal airway NO flux (J'_{awNO}) correlate with the bronchodilator response (BDR) only in the inhaled corticosteroid (ICS) naïve population. Distal airway/alveolar concentration (CANO) does not correlate with either steroid treated or steroid naïve subjects. Solid squares represent the ICS naïve patients and the circles represent the ICS treated patients.

REFERENCES

1. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. *J Allergy Clin Immunol* 2007;120(5 Suppl):S94-138.
2. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. *Am J Respir Crit Care Med* 1996;154(5):1505-1510.
3. Sutherland ER, Martin RJ, Bowler RP, Zhang Y, Rex MD, Kraft M. Physiologic correlates of distal lung inflammation in asthma. *J Allergy Clin Immunol* 2004;113(6):1046-1050.
4. Zacharasiewicz A, Wilson N, Lex C, Erin EM, Li AM, Hansel T, Khan M, Bush A. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. *Am J Respir Crit Care Med* 2005;171(10):1077-1082.
5. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. *Lancet* 2002;360(9347):1715-1721.
6. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. *Am J Respir Crit Care Med* 1999;159(4 Pt 1):1043-1051.
7. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. *Eur Respir J* 1993;6(9):1368-1370.
8. Lehtimäki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma. *Eur Respir J* 2001;18(4):635-639.
9. Berry M, Hargadon B, Morgan A, Shelley M, Richter J, Shaw D, Green RH, Brightling C, Wardlaw AJ, Pavord ID. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. *Eur Respir J* 2005;25(6):986-991.
10. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. *Am J Respir Crit Care Med* 2001;164(8 Pt 1):1376-1381.
11. Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, Koskela H, Brannan JD, Freed R, Andersson M, Chan HK, Woolcock AJ. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. *Am J Respir Crit Care Med* 2001;163(2):406-412.
12. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. *N Engl J Med* 2005;352(21):2163-2173.
13. Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. *Am J Respir Crit Care Med* 2007;176(3):231-237.
14. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. *J Appl Physiol* 1998;85(2):653-666.

15. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med* 2005;171(8):912-930.
16. Paraskakis E, Brindicci C, Fleming L, Krol R, Kharitonov SA, Wilson NM, Barnes PJ, Bush A. Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma. *Am J Respir Crit Care Med* 2006;174(3):260-267.
17. Lehtimäki L, Turjanmaa V, Kankaanranta H, Saarelainen S, Hahtola P, Moilanen E. Increased bronchial nitric oxide production in patients with asthma measured with a novel method of different exhalation flow rates. *Ann Med* 2000;32(6):417-423.
18. Mahut B, Delacourt C, Zerah-Lancner F, De Blic J, Harf A, Delclaux C. Increase in alveolar nitric oxide in the presence of symptoms in childhood asthma. *Chest* 2004;125(3):1012-1018.
19. Lehtimäki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. *Eur Respir J* 2002;20(4):841-845.
20. Puckett JL, George SC. Partitioned exhaled nitric oxide to non-invasively assess asthma. *Respir Physiol Neurobiol* 2008;163(1-3):166-177.
21. Spahn JD, Cherniack R, Paull K, Gelfand EW. Is forced expiratory volume in one second the best measure of severity in childhood asthma? *Am J Respir Crit Care Med* 2004;169(7):784-786.
22. Covar RA, Szeffler SJ, Martin RJ, Sundstrom DA, Silkoff PE, Murphy J, Young DA, Spahn JD. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. *J Pediatr* 2003;142(5):469-475.
23. Faul JL, Demers EA, Burke CM, Poulter LW. Alterations in airway inflammation and lung function during corticosteroid therapy for atopic asthma. *Chest* 2002;121(5):1414-1420.
24. Strunk RC, Szeffler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, Morgan W, Sorkness CA, Lemanske RF, Jr. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. *J Allergy Clin Immunol* 2003;112(5):883-892.
25. Goleva E, Hauk PJ, Boguniewicz J, Martin RJ, Leung DY. Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. *J Allergy Clin Immunol* 2007;120(5):1065-1072.
26. Martin RJ, Szeffler SJ, King TS, Kraft M, Boushey HA, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fahy JV, Israel E, Lazarus SC, Lemanske RF, Jr., Leone FT, Pesola GR, Peters SP, Sorkness CA, Szwejbka LA, Wechsler ME. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. *J Allergy Clin Immunol* 2007;119(1):73-80.
27. Tantisira KG, Fuhlbrigge AL, Tonascia J, Van Natta M, Zeiger RS, Strunk RC, Szeffler SJ, Weiss ST. Bronchodilation and bronchoconstriction: predictors of future lung function in childhood asthma. *J Allergy Clin Immunol* 2006;117(6):1264-1271.

28. Colon-Semidey AJ, Marshik P, Crowley M, Katz R, Kelly HW. Correlation between reversibility of airway obstruction and exhaled nitric oxide levels in children with stable bronchial asthma. *Pediatr Pulmonol* 2000;30(5):385-392.
29. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, Rosenzweig JC, Manjunath R. Development and cross-sectional validation of the Childhood Asthma Control Test. *J Allergy Clin Immunol* 2007;119(4):817-825.
30. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol* 2004;113(1):59-65.
31. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. *Am Rev Respir Dis* 1991;144(5):1202-1218.
32. Condorelli P, Shin HW, Aledia AS, Silkoff PE, George SC. A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. *J Appl Physiol* 2007;102(1):417-425.
33. George SC, Hogman M, Permutt S, Silkoff PE. Modeling pulmonary nitric oxide exchange. *J Appl Physiol* 2004;96(3):831-839.
34. Sepponen A, Lehtimäki L, Huhtala H, Kaila M, Kankaanranta H, Moilanen E. Alveolar and bronchial nitric oxide output in healthy children. *Pediatr Pulmonol* 2008;43(12):1242-1248.
35. Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF, Jr., Sorkness CA. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. *Am J Respir Crit Care Med* 2004;170(4):426-432.
36. Dundas I, Chan EY, Bridge PD, McKenzie SA. Diagnostic accuracy of bronchodilator responsiveness in wheezy children. *Thorax* 2005;60(1):13-16.
37. Galant SP, Morphew T, Amaro S, Liao O. Value of the bronchodilator response in assessing controller naive asthmatic children. *J Pediatr* 2007;151(5):457-462, 462 e451.
38. Sharma S, Litonjua AA, Tantisira KG, Fuhlbrigge AL, Szeffler SJ, Strunk RC, Zeiger RS, Murphy AJ, Weiss ST. Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program. *J Allergy Clin Immunol* 2008;122(5):921-928 e924.
39. Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. *Thorax* 2000;55(3):232-234.
40. Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P, Taylor DR. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. *Am J Respir Crit Care Med* 2004;169(4):473-478.
41. Beck-Ripp J, Griese M, Arenz S, Koring C, Pasqualoni B, Bufler P. Changes of exhaled nitric oxide during steroid treatment of childhood asthma. *Eur Respir J* 2002;19(6):1015-1019.
42. de Jongste JC, Carraro S, Hop WC, Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. *Am J Respir Crit Care Med* 2009;179(2):93-97.

43. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. *Am J Respir Crit Care Med* 2005;172(7):831-836.
44. Szeffler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, Kattan M, Pongracic JA, Teach SJ, Bloomberg GR, Eggleston PA, Gruchalla RS, Kercksmar CM, Liu AH, Wildfire JJ, Curry MD, Busse WW. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. *Lancet* 2008;372(9643):1065-1072.
45. Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASThma Treatment ALgorithm studies. *Clin Exp Allergy* 2009;39(4):478-490.
46. Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma. *Curr Opin Pulm Med* 2009;15(1):57-62.
47. Buchvald F, Baraldi E, Carraro S, Gaston B, De Jongste J, Pijnenburg MW, Silkoff PE, Bisgaard H. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. *J Allergy Clin Immunol* 2005;115(6):1130-1136.
48. Ho LP, Wood FT, Robson A, Innes JA, Greening AP. Atopy influences exhaled nitric oxide levels in adult asthmatics. *Chest* 2000;118(5):1327-1331.
49. Jouaville LF, Annesi-Maesano I, Nguyen LT, Bocage AS, Bedu M, Caillaud D. Interrelationships among asthma, atopy, rhinitis and exhaled nitric oxide in a population-based sample of children. *Clin Exp Allergy* 2003;33(11):1506-1511.
50. Venegas JG, Winkler T, Musch G, Vidal Melo MF, Layfield D, Tgavalekos N, Fischman AJ, Callahan RJ, Bellani G, Harris RS. Self-organized patchiness in asthma as a prelude to catastrophic shifts. *Nature* 2005;434(7034):777-782.
51. Suresh V, Shelley DA, Shin HW, George SC. Effect of heterogeneous ventilation and nitric oxide production on exhaled nitric oxide profiles. *J Appl Physiol* 2008;104(6):1743-1752.
52. Kumar R, Wang B, Wang X, Chen C, Yang J, Fu L, Xu X. Bronchodilator responses in Chinese children from asthma index families and the general population. *J Allergy Clin Immunol* 2006;117(6):1257-1263.

Table 1. Demographics of subjects and baseline spirometry

	Non-Asthmatic Non-atopic Control (n = 21)	ICS Treated Asthma (n = 110)	ICS Naïve Asthma (n = 69)	Overall test p-value [#]	Paired comparison result [§]
Age, years	10 (6 – 17)	11 (6 – 17)	10 (6 – 17)	0.57	----
Gender Male	12 (57%)	45 (65%)	72 (65%)	0.57	----
Atopic	----	82 (75%)	59 (86%)	0.1	----
ACT	----	22 11-27	20 10-27	0.007	ICS Treated >ICS Naïve
FEV ₁ (%)	106 (93 – 118)	105 (75 – 149)	108 (67 – 149)	0.63	----
FVC (%)	104 (89 – 124)	106 (73 – 147)	106 (71 – 145)	0.82	----
FEV ₁ /FVC (%)	90 (84 – 102)	87 (70 – 100)	88 (72 – 101)	0.032	Control > ICS Treated
FEF ₂₅₋₇₅ (%)	103 (90 – 176)	100 (45 – 185)	107 (48 – 178)	0.24	----

Data is presented as median (range).

ICS, inhaled corticosteroid; ACT score (≤ 19 indicative of poor asthma control, scale 0-30)

[#]Chi-square test for Gender and Atopic and Kruskal-Wallis test for all other variables.

[§]Bonferroni's multiple comparison adjustment was applied for paired comparison.

Table 2. BDR and baseline exhaled nitric oxide parameters

	Non-Asthmatic Non-atopic Control (n = 21)	ICS Treated Asthma (n = 110)	ICS Naïve Asthma (n = 69)	Overall test p-value [#]	Paired comparison result ^{\$}
BDR (%)	5.3 (0.6 – 6.6) [n = 13]	6 (0 – 22.5) [n = 102]	6.8 (0.7 – 35.5) [n = 69]	0.041	none
FE _{NO,50} (ppb)	8.5 (2.2 – 15.3)	13.8 (3.7 – 158.4)	36.1 (5.1 – 186.2)	<0.0001	Control < ICS Treated < ICS Naive
J'aw _{NO} (nl/s)	0.7 (0.1 – 1.4)	1.1 (0.1 – 14)	2.8 (0.2 – 17)	<0.0001	Control < ICS Treated < ICS Naive
CA _{NO} (ppb)	1.5 (0.1 – 2.2)	1 (0.006 – 5.1)	1.5 (0.02 – 13.4)	0.032	ICSTreated < ICS Naive

Data is presented as median (range).

ICS, inhaled corticosteroids.

[#] Kruskal-Wallis test for all other variables. ^{\$} Bonferroni's multiple comparison adjustment was applied for paired comparison.

Table 3. Effect of varying the BDR cut point on sensitivities, specificities, positive predictor values and negative predictive values.

	<u>BDR ≥ 8%</u>	<u>BDR ≥ 9%</u>	<u>BDR ≥ 10%</u>	<u>BDR ≥ 11%</u>	<u>BDR ≥ 12%</u>
<i>FE_{NO,50}</i>					
<i>SENSITIVITY (%)</i>	49	45	39	33	31
<i>SPECIFICITY (%)</i>	69	75	81	94	100
<i>PPV (%)</i>	83	85	86	94	100
<i>NPV (%)</i>	31	31	30	31	32
<i>J'aw_{NO}</i>					
<i>SENSITIVITY (%)</i>	50	46	40	33	31
<i>SPECIFICITY (%)</i>	71	76	82	94	100
<i>PPV (%)</i>	83	85	86	94	100
<i>NPV (%)</i>	33	33	33	33	34

BDR, bronchodilator response; $FE_{NO,50}$, exhaled nitric oxide at a flow of 50 ml/s; $J'aw_{NO}$, maximum airway nitric oxide flux; PPV, positive predictor value; NPV, negative predictor value.

